Bioporto ASTHOXF 69 Cyclically Adjusted PS Ratio is 4.97 as of Jul. 08, 2026, which is 64% below its 10-year median of 13.74. GuruFocus rates THOXF with a GF Score™ of 69/100 and a GF Value™ of $0.16. The stock has 3 warning signs investors should review. Among 135 Medical Diagnostics & Research companies, Bioporto AS ranks worse than 85.19% on this metric.
The historical rank and industry rank for Bioporto AS's Cyclically Adjusted PS Ratio or its related term are showing as below:
THOXF'
s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 7.23 Med: 13.74 Max: 39.07
Current: 9.12
During the past years, Bioporto AS's highest Cyclically Adjusted PS Ratio was 39.07. The lowest was 7.23. And the median was 13.74.
THOXF's Cyclically Adjusted PS Ratio is ranked worse than 85.19% of 135
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.01
vs THOXF: 9.12
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Bioporto AS's adjusted revenue per share data for the three months ended in Dec. 2025 was $0.004. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $0.03 for the trailing ten years ended in Dec. 2025.
Shiller PE for Stocks: The True Measure of Stock Valuation
Bioporto AS (OTCPK:THOXF) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Bioporto AS Cyclically Adjusted PS Ratio Related Terms
Bioporto AS Cyclically Adjusted PS Ratio Historical Data
* Premium members only.
The historical data trend for Bioporto AS's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
THOXF vs TMO, DHR, IDXX: Cyclically Adjusted PS Ratio Comparison
For the Diagnostics & Research subindustry, Bioporto AS's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bioporto AS Cyclically Adjusted PS Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Bioporto AS's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Bioporto AS's Cyclically Adjusted PS Ratio falls into.
Bioporto AS Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
Bioporto AS's Cyclically Adjusted PS Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 4.97 mean?
Bioporto AS (THOXF) has a Cyclically Adjusted PS Ratio of 4.97 as of Jul. 08, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Bioporto AS and its competitors. This is 64% below median its historical median of 13.74. Over the past decade, Bioporto AS's Cyclically Adjusted PS Ratio has ranged from 7.23 to 39.07. According to the industry distribution chart, Bioporto AS ranks #115 out of 135 companies in the Medical Diagnostics & Research industry, placing it in the top 85.2%.
Is Bioporto AS's Cyclically Adjusted PS Ratio too high?
Bioporto AS's current Cyclically Adjusted PS Ratio of 4.97 is 64% below median its 10-year median of 13.74. Over the past 10 years, this metric has ranged from a low of 7.23 to a high of 39.07. The Medical Diagnostics & Research industry median Cyclically Adjusted PS Ratio is 2.01. Bioporto AS's value of 4.97 is 147.3% above this industry median. Based on the distribution chart, Bioporto AS ranks #115 out of 135 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Bioporto AS has a GF Score™ of 69/100, reflecting its overall financial health beyond just this single metric.
How does Bioporto AS's Cyclically Adjusted PS Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Bioporto AS ranks #115 out of 135 companies for Cyclically Adjusted PS Ratio. This places Bioporto AS in the lower half of its industry. The industry median Cyclically Adjusted PS Ratio is 2.01. Bioporto AS's value of 4.97 is 147.3% above this benchmark. Historically, Bioporto AS's own Cyclically Adjusted PS Ratio has ranged from 7.23 to 39.07 over the past decade. While the company's 10-year median is 13.74 vs. the industry median of 2.01, Bioporto AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Medical Diagnostics & Research company?
The median Cyclically Adjusted PS Ratio among Medical Diagnostics & Research companies is 2.01, based on 135 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bioporto AS's current Cyclically Adjusted PS Ratio of 4.97 is 147.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Bioporto AS and its competitors. For the Medical Diagnostics & Research industry, the median Cyclically Adjusted PS Ratio is 2.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bioporto AS's current Cyclically Adjusted PS Ratio is 4.97, which is 64% below median its own 10-year median of 13.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioporto AS stock overvalued right now?
Bioporto AS (THOXF) has a current Cyclically Adjusted PS Ratio of 4.97. The stock's GF Value™ is $0.16, compared to a current price of $0.15 — trading 6.9% below its estimated fair value. The current Cyclically Adjusted PS Ratio is 4.97, which is 64% below median its 10-year median of 13.74 and 147.3% above the Medical Diagnostics & Research industry median of 2.01. Bioporto AS's overall GF Score™ is 69/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For Bioporto AS (THOXF), the current Cyclically Adjusted PS Ratio is 4.97 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bioporto AS (THOXF) Overvalued in 2026?
Based on GuruFocus' analysis, Bioporto AS stock appears to be undervalued.
The current stock price of $0.15 is trading 6.9% below its estimated GF Value™ of $0.16.
Key valuation signals for THOXF:
Cyclically Adjusted PS Ratio: 4.97 (64% below median its 10-year median of 13.74)
GF Value™: $0.16 vs. price of $0.15 (6.9% below fair value)
Industry Position: 147.3% above the Medical Diagnostics & Research median (#115 of 135)
No single metric tells the full story. See the THOXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioporto AS is an in-vitro diagnostic company. The company provides healthcare professionals in clinical and research settings with a range of diagnostic tests and antibodies. Its product portfolio consists of specialized monoclonal antibodies and antibody-based diagnostic assays, used in the treatment of critically ill patients. The company's products include the NGAL Test, ELISA kits, Antibodies, and Other products and licenses. Geographically, it derives a majority of its revenue from North America. Geographically, its business area is in North America, Denmark, and rest of Europe, and Asia. The products of the company involve: ProNephro AKI, The NGAL Test, Antibodies, ELISA Kits, gRad Lateral Flow, and others.
69GF Score
Get the complete analysis for THOXF
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
THOXF has been successfully added to your 
